What is the clinical evidence from this study?

Study design: Cohort. Population: Non-ST segment elevation acute coronary syndrome (NSTEACS) (n=224). Intervention: Admission B-type natriuretic peptide (BNP) ≥ 100 pg/mL vs. BNP < 100 pg/mL. Primary outcome: All-cause mortality (RR 3.76, 95% CI 2.49-5.63, p=<0.001).

January 1, 2016Arquivos Brasileiros de CardiologiaOpen Access

Very Long-Term Prognostic Role of Admission BNP in Non-ST Segment Elevation Acute Coronary Syndrome

Q: What are the key findings of this study?

Admission BNP ≥ 100 pg/mL in patients with non-ST segment elevation acute coronary syndrome was associated with a 65.0% long-term mortality rate compared to 17.3% for BNP < 100 pg/mL (RR 3.76).

View Full Paper

Ask AI

Bookmark

Key result

Admission BNP ≥ 100 pg/mL in patients with non-ST segment elevation acute coronary syndrome was associated with a 65.0% long-term mortality rate compared to 17.3% for BNP < 100 pg/mL (RR 3.76).

Why the study?

Does admission BNP predict very long-term all-cause mortality in patients with NSTEACS?

Population

224 consecutive patients with non-ST segment elevation acute coronary syndrome prospectively seen in the…

Comparison

Admission B-type natriuretic peptide measurement vs BNP < 100 pg/mL

Design

Cohort

Follow-up

median 9.34 years

Authors

FBFernando Bassan RBRoberto Bassan RERoberto Esporcatte

Discussion

Member takes

Overview

Supports BNP for long-term NSTEACS prognosis; hypothesis-generating and should not yet change practice.

Study Design

Type

Cohort (n=224)

Multicenter

Structured PICO

Does admission BNP predict very long-term all-cause mortality in patients with NSTEACS?

Population

224 patients with non-ST segment elevation acute coronary syndrome, prospectively evaluated in the emergency department and followed for a median of 9.34 years for all-cause mortality.

Exposure

Admission B-type natriuretic peptide (BNP) measurement (specifically BNP ≥ 100 pg/mL)

Comparator

BNP < 100 pg/mL

Outcome

All-cause mortality at median 9.34-year follow-uphard clinical

Main Result

Relative Risk: 3.76 (95% CI 2.49–5.63)

Absolute Event Rate: 65% vs 17.3%

p-value: p=<0.001

Admission BNP ≥ 100 pg/mL is a strong, independent predictor of very long-term all-cause mortality in patients with NSTEACS.

Limitations

Relatively small sample size in comparison with other cited multicenter studies
Originates from a single, private, cardiology-oriented institution
Does not address the possible value of serial BNP measurements
Troponin assay used is of an older generation (non-high sensitive)

Cite This Study

Bassan et al. (2016) conducted a cohort in Non-ST segment elevation acute coronary syndrome (NSTEACS) (n=224). Admission B-type natriuretic peptide (BNP) ≥ 100 pg/mL vs. BNP < 100 pg/mL was evaluated on All-cause mortality (RR 3.76, 95% CI 2.49-5.63, p=<0.001). Admission BNP ≥ 100 pg/mL in patients with non-ST segment elevation acute coronary syndrome was associated with a 65.0% long-term mortality rate compared to 17.3% for BNP < 100 pg/mL (RR 3.76).

synapsesocial.com/papers/6a9466a85e508145153edaed https://doi.org/10.5935/abc.20160021

View Full Paper

Ask AI

Bookmark

January 1, 2016Arquivos Brasileiros de CardiologiaOpen Access

Very Long-Term Prognostic Role of Admission BNP in Non-ST Segment Elevation Acute Coronary Syndrome

View Full Paper

Ask AI

Bookmark

Key result

Admission BNP ≥ 100 pg/mL in patients with non-ST segment elevation acute coronary syndrome was associated with a 65.0% long-term mortality rate compared to 17.3% for BNP < 100 pg/mL (RR 3.76).

Why the study?

Does admission BNP predict very long-term all-cause mortality in patients with NSTEACS?

Population

224 consecutive patients with non-ST segment elevation acute coronary syndrome prospectively seen in the…

Comparison

Admission B-type natriuretic peptide measurement vs BNP < 100 pg/mL

Design

Cohort

Follow-up

median 9.34 years

Authors

FBFernando Bassan RBRoberto Bassan RERoberto Esporcatte

Discussion

Member takes

Overview

Supports BNP for long-term NSTEACS prognosis; hypothesis-generating and should not yet change practice.

Study Design

Type

Cohort (n=224)

Multicenter

Structured PICO

Does admission BNP predict very long-term all-cause mortality in patients with NSTEACS?

Population

224 patients with non-ST segment elevation acute coronary syndrome, prospectively evaluated in the emergency department and followed for a median of 9.34 years for all-cause mortality.

Exposure

Admission B-type natriuretic peptide (BNP) measurement (specifically BNP ≥ 100 pg/mL)

Comparator

BNP < 100 pg/mL

Outcome

All-cause mortality at median 9.34-year follow-uphard clinical

Main Result

Relative Risk: 3.76 (95% CI 2.49–5.63)

Absolute Event Rate: 65% vs 17.3%

p-value: p=<0.001

Admission BNP ≥ 100 pg/mL is a strong, independent predictor of very long-term all-cause mortality in patients with NSTEACS.

Limitations

Relatively small sample size in comparison with other cited multicenter studies
Originates from a single, private, cardiology-oriented institution
Does not address the possible value of serial BNP measurements
Troponin assay used is of an older generation (non-high sensitive)

Cite This Study

synapsesocial.com/papers/6a9466a85e508145153edaed https://doi.org/10.5935/abc.20160021

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark